Semaglutide vs Tirzepatide: Head-to-Head Comparison
Both are FDA-approved for type 2 diabetes and obesity. Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist, while tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist. Clinical trials show tirzepatide achieves greater weight loss on average, but both are considered breakthrough therapies.
Side-by-Side Comparison
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Evidence Level | Phase III (STEP trials); extensive real-world data | Phase III (SURMOUNT/SURPASS trials); newer but robust |
| FDA Status | FDA-approved for T2D (Ozempic) and obesity (Wegovy) | FDA-approved for T2D (Mounjaro) and obesity (Zepbound) |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Weight Loss Efficacy | ~15-17% body weight loss in trials | ~20-22.5% body weight loss in trials |
| Side Effects | Nausea, vomiting, diarrhea, pancreatitis risk | Nausea, vomiting, diarrhea (similar GI profile) |
| Dosing | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Cost | ~$1,000-1,300/month (brand) | ~$1,000-1,200/month (brand) |
Peptide Overviews
Semaglutide
AFDA ApprovedSemaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Semaglutide vs Tirzepatide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.